8-K current report · filed Oct 28, 2026

Vir Biotechnology, Inc. (VIR) 8-K Current Report: October 28, 2026

Item 5.02VIR overview

Short answer

Vir Biotechnology, Inc. (VIR) filed an 8-K current report with the SEC on October 28, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Board expanded from eight to nine directors, adding Suzanne Topalian, M.D. through the 2028 annual meeting.

Vir Biotechnology, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Board expanded from eight to nine directors, adding Suzanne Topalian, M.D. through the 2028 annual meeting
  • Topalian joins the Science and Technology Committee, strengthening board-level scientific oversight
  • New director receives standard cash compensation, stock options and restricted stock units under Vir’s policy
  • Appointment included standard director indemnification, with no disclosed related-party transactions or selection arrangements

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Vir Biotechnology, Inc. 8-K filings

Get the next VIR 8-K as it lands

Follow VIR for push alerts, or ask the research agent what this filing means.